‘C-Tri’ has first acquired the oral treatment for spinocerebellar degeneration in Korea
The pharmaceutical company specializing in the non-natureamino acid mass production technology and peptide,‘C-Tri’ (CEO Wan-ju Kim), has acquired the domestic approval to manufacture and sell ‘Citrelin ODT 5mg’ on the last 6th for the first time.
On every treatment for spinocerebellar degenerati...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
